BCMA mRNA CAR-T Shows Durable Benefit in MG

For patients with refractory generalized myasthenia gravis (MG), durable disease control remains an unmet goal. In the Phase 2a MG-001 trial, investigators report sustained clinical responses after a time-limited course of Descartes-08, a B-cell maturation antigen (BCMA)-directed mRNA chimeric antigen receptor T-cell (CAR-T) therapy.

The findings invite careful optimism that targeted plasma cell depletion, without lymphodepletion or genomic integration associated with lentiviral vectors during the creation of conventional CAR-Ts, may meaningfully reshape how we approach antibody-mediated autoimmunity.

BCMA and mRNA CAR-T Design
BCMA is expressed on plasmablasts and long-lived plasma cells, which are the principal producers of pathogenic autoantibodies in MG as well as plasmacytoid dendritic cells. Descartes-08 uses autologous T cells transiently engineered with mRNA to express a BCMA-specific CAR. Unlike DNA-integrating CAR-T platforms, mRNA-based constructs do not integrate into the genome and are not dependent on in vivo T-cell expansion for efficacy. T cells are expanded ex vivo during manufacturing, allowing controlled dosing in the outpatient setting and eliminating the need for lymphodepleting chemotherapy.

This approach reduces risks associated with genomic integration, prolonged cytopenias, and cytokine release syndrome (CRS), which have been observed with conventional CAR-T approaches.

Study Design
MG-001 was a multicenter, open-label Phase 1/2a trial conducted across eight U.S. centers. The 12-month durability analysis focuses on seven participants in Arm-2 who received 52.5 × 10⁶ viable CAR+ cells/kg once weekly for six weeks without lymphodepletion. Participants had MGFA Class II–IV disease and included AChR antibody-positive, MuSK antibody-positive, and seronegative MG. Participants were on stable background immunosuppression, and they’d had prior exposure to immunosuppressants and IVIG. No increase in therapy or new therapy was permitted during the trial period.

Clinical outcomes were assessed using validated instruments, including the MG Activities of Daily Living (MG-ADL) scale, MG Composite (MGC), Quantitative MG (QMG), and MG Quality of Life 15-revised score (MG-QoL15r). Cytokine profiling, autoantibody titers, vaccine titers, and immunoglobulin levels were monitored longitudinally.

Clinical Durability
At month 9, all seven participants maintained substantial improvement:

• MG-ADL: mean change −6.3
• MGC: −16.6
• QMG: −8.4
• QoL-15r: −12

By Month 12, 5 of the 7 participants sustained clinically meaningful improvement, including one with minimal symptom expression (MSE). Mean changes at month 12 included:

• MG-ADL: −4.6
• MGC: −11.3
• QMG: −6.3
• QoL-15r: −7.7

Notably, median prednisone dose decreased from 17.5 mg at baseline to 5 mg at month 12, and neither of the two IVIG-dependent participants required IVIG during follow-up.

Three participants experienced relapse at 12-18 months and underwent retreatment with six weekly infusions. All demonstrated rapid clinical improvement; two achieved MSE by Week 8 and maintained benefit through 12 months post-retreatment.

Autoantibodies and Cytokines
Reductions in anti-AChR antibody levels paralleled clinical durability. Among the three eligible AChR-positive participants, reductions included:

• Month 6: −17%, −44%, −65%
• Month 9: −35%, −100% (undetectable), −70%
• Month 12: −33%, −44%, −65%

IL-17A levels decreased from 58.2 pg/mL pretreatment to 0 pg/mL at Month 3 (p=0.018), while other pro-inflammatory cytokines trended downward.

Importantly, total immunoglobulin levels remained stable, and vaccine titers, including anti-meningococcal antibodies, remained at protective levels despite partial reductions.

The delayed peak antibody reduction, which occurred approximately 4-6 months after the last infusion, aligns with depletion of antibody-producing plasma cells rather than direct immunoglobulin neutralization. The rapid clinical response preceding maximal antibody decline raises intriguing questions about tissue-level effects and the potential contribution of BCMA-positive plasmacytoid dendritic cell targeting.

Safety Profile
There were no reported cases of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS). Because lymphodepleting chemotherapy was not used, there were no associated cytopenias. Additionally, no treatment-related infections were observed during the 12-month follow-up period, and no cases of anaphylaxis were reported

One participant experienced grade 3 urticaria in the dose-escalation phase. Overall, the safety profile contrasts with reports of severe neutropenia, CRS (75%), and ICANS (6%) in DNA-based CAR-T use for autoimmune disease.

Clinical Implications
This small, open-label study cannot establish comparative efficacy or long-term remission rates. Yet the convergence of clinical durability, biologic plausibility, and a favorable safety profile suggests that BCMA-directed mRNA CAR-T therapy may offer a fundamentally different therapeutic trajectory for refractory MG.

References:
Chahin N, Sahagian G, Feinberg MH, et al. Durability of Response to B-Cell Maturation Antigen-Directed mRNA Cell Therapy in Myasthenia Gravis. Ann Clin Transl Neurol. 2025;12(11):2358-2366. doi:10.1002/acn3.70167